TATE and KN046 in MCRC
A single-arm, multicenter, Phase IIA study of Intra-arterial Administration of Tirapazamine followed by Transarterial Embolization (TATE) and KN046 (recombinant humanized anti-PD-L1/CTLA-4 bispecific single-domain antibody Fc fusion protein injection) in patients with liver metastases from colorectal cancer.
Colorectal Cancer with Hepatic Metastases
DRUG: KN046 （PD-L1/CTLA4 BsAb）|PROCEDURE: TATE：Intra-arterial Administration of Tirapazamine followed by Transarterial Embolization
ORR, Objective Response Rate (assessed by mRECIST/RECIST), 24 months|OS, Overall Survival, 24 months
DCR, Disease control rate, 24 months|PFS, Progression-free survival, 24 months|survival rates, 6-month, 1-year, and 2-year survival rates, 24 months
A single-arm, multicenter, Phase IIA study of Intra-arterial Administration of Tirapazamine followed by Transarterial Embolization (TATE) and KN046 (recombinant humanized anti-PD-L1/CTLA-4 bispecific single-domain antibody Fc fusion protein injection) in patients with liver metastases from colorectal cancer.